Company intelligence / Profile preview

Xanthus Pharmaceuticals, Inc.

Cambridge, Massachusetts, United Statesbiospace.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Xanthus Pharmaceuticals developed a portfolio of novel, clinical-stage small-molecule therapeutics targeting oncology and autoimmune diseases. At the time of its acquisition by Antisoma plc in May 2008 for $52.2 million, it had multiple compounds in clinical development but no approved products. The company’s management team had experience across all aspects of drug development from discovery to commercialization. No recent or current clinical results are available post-acquisition.

Therapeutic areas: OncologyImmunology
Modalities: small molecules
Industry: Biotech

Beyond the preview

Go deeper on Xanthus Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xanthus Pharmaceuticals, Inc..

Explore the full profile